328 related articles for article (PubMed ID: 32957843)
1. Micronized progesterone, progestins, and menopause hormone therapy.
Hipolito Rodrigues MA; Gompel A
Women Health; 2021 Jan; 61(1):3-14. PubMed ID: 32957843
[TBL] [Abstract][Full Text] [Related]
2. Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy.
Gompel A
Climacteric; 2018 Aug; 21(4):321-325. PubMed ID: 29583028
[TBL] [Abstract][Full Text] [Related]
3. The impact of micronized progesterone on breast cancer risk: a systematic review.
Stute P; Wildt L; Neulen J
Climacteric; 2018 Apr; 21(2):111-122. PubMed ID: 29384406
[TBL] [Abstract][Full Text] [Related]
4. Progesterone, progestins and the breast in menopause treatment.
Gompel A; Plu-Bureau G
Climacteric; 2018 Aug; 21(4):326-332. PubMed ID: 29852797
[TBL] [Abstract][Full Text] [Related]
5. Progesterone or progestin as menopausal ovarian hormone therapy: recent physiology-based clinical evidence.
Prior JC
Curr Opin Endocrinol Diabetes Obes; 2015 Dec; 22(6):495-501. PubMed ID: 26512775
[TBL] [Abstract][Full Text] [Related]
6. Is breast cancer risk the same for all progestogens?
Stute P
Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
[TBL] [Abstract][Full Text] [Related]
7. Micronized progesterone and its impact on the endometrium and breast vs. progestogens.
Gompel A
Climacteric; 2012 Apr; 15 Suppl 1():18-25. PubMed ID: 22432812
[TBL] [Abstract][Full Text] [Related]
8. The impact of micronized progesterone on the endometrium: a systematic review.
Stute P; Neulen J; Wildt L
Climacteric; 2016 Aug; 19(4):316-28. PubMed ID: 27277331
[TBL] [Abstract][Full Text] [Related]
9. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
Cobin RH; Goodman NF;
Endocr Pract; 2017 Jul; 23(7):869-880. PubMed ID: 28703650
[TBL] [Abstract][Full Text] [Related]
10. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal.
L'Hermite M
Climacteric; 2017 Aug; 20(4):331-338. PubMed ID: 28301216
[TBL] [Abstract][Full Text] [Related]
11. Comparative cardiovascular effects of different progestins in menopause.
Rosano GM; Fini M
Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
[TBL] [Abstract][Full Text] [Related]
12. Management of postmenopausal women: Collège National des Gynécologues et Obstétriciens Français (CNGOF) and Groupe d'Etude sur la Ménopause et le Vieillissement (GEMVi) Clinical Practice Guidelines.
Trémollieres FA; Chabbert-Buffet N; Plu-Bureau G; Rousset-Jablonski C; Lecerf JM; Duclos M; Pouilles JM; Gosset A; Boutet G; Hocke C; Maris E; Hugon-Rodin J; Maitrot-Mantelet L; Robin G; André G; Hamdaoui N; Mathelin C; Lopes P; Graesslin O; Fritel X
Maturitas; 2022 Sep; 163():62-81. PubMed ID: 35717745
[TBL] [Abstract][Full Text] [Related]
13. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis.
Asi N; Mohammed K; Haydour Q; Gionfriddo MR; Vargas OL; Prokop LJ; Faubion SS; Murad MH
Syst Rev; 2016 Jul; 5(1):121. PubMed ID: 27456847
[TBL] [Abstract][Full Text] [Related]
14. The menopause: benefits and risks of estrogen-progestogen replacement therapy.
Gambrell RD
Fertil Steril; 1982 Apr; 37(4):457-74. PubMed ID: 7040116
[TBL] [Abstract][Full Text] [Related]
15. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.
Campagnoli C; Clavel-Chapelon F; Kaaks R; Peris C; Berrino F
J Steroid Biochem Mol Biol; 2005 Jul; 96(2):95-108. PubMed ID: 15908197
[TBL] [Abstract][Full Text] [Related]
16. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
Simoncini T; Genazzani AR
Climacteric; 2010 Feb; 13(1):22-33. PubMed ID: 19938948
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy, progesterone and progestins in relation to breast cancer risk.
Campagnoli C; Abbà C; Ambroggio S; Peris C
J Steroid Biochem Mol Biol; 2005 Dec; 97(5):441-50. PubMed ID: 16249080
[TBL] [Abstract][Full Text] [Related]
18. 17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review.
Mirkin S; Amadio JM; Bernick BA; Pickar JH; Archer DF
Maturitas; 2015 May; 81(1):28-35. PubMed ID: 25835751
[TBL] [Abstract][Full Text] [Related]
19. Postmenopausal hormone replacement therapy--clinical implications.
Ravn SH; Rosenberg J; Bostofte E
Eur J Obstet Gynecol Reprod Biol; 1994 Feb; 53(2):81-93. PubMed ID: 8194655
[TBL] [Abstract][Full Text] [Related]
20. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
Cordina-Duverger E; Truong T; Anger A; Sanchez M; Arveux P; Kerbrat P; Guénel P
PLoS One; 2013; 8(11):e78016. PubMed ID: 24223752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
